Immune Cells in the Tumor Microenvironment II

Moderator(s)

• WZ

  Weiping Zou

  University of Michigan
• QW

  Qiwei Wang

  University of Virginia

Presentations:

• 8:00 AM - 8:15 AM US ET

  Type I Interferon priming in Macrophages is associated with poor responses in Patients with Advanced Prostate Cancer
  

  Author: David E. Sanin, PhD (he/him/his) – Johns Hopkins Univ. Sch. of Med.
• 8:15 AM - 8:30 AM US ET

  T6B-mediated inhibition of the miRISC decreases myeloid-derived suppressor cell abundance and enhances survival in a murine ovarian cancer model
  

  Author: Joshua Imperatore, PhD (he/him/his) – Magee-Womens Res. Inst. & Fndn.
• 8:30 AM - 8:45 AM US ET

  AXL tyrosine kinase inhibition restores anti-PD-1 efficacy in melanoma through tumor-associated macrophage–dependent mechanisms
  

  Author: Amanda Kirane – Stanford University
• 8:45 AM - 9:00 AM US ET

  Loss of the Y chromosome evokes extrinsic extramedullary myelopoiesis via genome-wide epigenetic reprogramming of bladder cancer tumor cells
  

  Author: Jay Mandula, PhD, BS (he/him/his) – Ohio State University
• 9:00 AM - 9:15 AM US ET

  Immune organ tertiary lymphoid structures (TLSs) as a therapeutic strategy for solid tumors
  

  Author: Sudip Paudel, PhD – Wyss Institute